Gastroenterology
Volume 137, Issue 2 , Pages 502-511 , August 2009

Time Trends in Therapies and Outcomes for Adult Inflammatory Bowel Disease, Northern California, 1998–2005

  • Lisa J. Herrinton

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • Corresponding Author InformationReprint requests Address requests for reprints to: Lisa J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California, 2000 Broadway Avenue, Oakland, California 94612. fax: (510) 891-3761
    • ,
  • Liyan Liu

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • ,
  • Bruce Fireman

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • ,
  • James D. Lewis

      Affiliations

    • Department of Medicine, Department of Biostatistics and Epidemiology, and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • James E. Allison

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • Division of Gastroenterology, Department of Internal Medicine, University of California, San Francisco, California
    • ,
  • Nicole Flowers

      Affiliations

    • Emerging Investigations and Analytic Methods Branch, Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
    • ,
  • Susan Hutfless

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
    • ,
  • Fernando S. Velayos

      Affiliations

    • Division of Gastroenterology, Department of Internal Medicine, University of California, San Francisco, California
    • ,
  • Oren Abramson

      Affiliations

    • Division of Pediatric Gastroenterology, Kaiser Permanente, Santa Clara, California
    • ,
  • Andrea Altschuler

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • ,
  • Geraldine S. Perry

      Affiliations

    • Emerging Investigations and Analytic Methods Branch, Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

Received 3 December 2008 ,Accepted 24 April 2009.

References 

  1. Caprilli R, Michetti P. The European Panel on the Appropriateness of Crohn's Disease Therapy. Digestion. 2005;71:6–7
  2. Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007;26:987–1003
  3. Sandborn WJ. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord. 2006;6:97–105
  4. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000;2:CD000067
  5. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95:3469–3477
  6. Kane SV, Schoenfeld P, Sandborn WJ, et al. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 2002;16:1509–1517
  7. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol. 1994;89:2116–2124
  8. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465–1473
  9. Kamm MA. Debate: should mesalamine be used in Crohn's disease? comments and conclusion. Inflamm Bowel Dis. 2005;11:616–617
  10. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657
  11. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619
  12. Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996–2002. Am Journal Gastroenterol. 2008;103:1998–2006
  13. Getting Started with SAS's PROC MIXED: Analyzing Fixed Effects that Apply to Clustered Data. http://cc.uoregon.edu/cnews/summer2004/procmixed.htmAccessed September 20, 2007
  14. Greenland S. Bayesian perspectives for epidemiological research, II: regression analysis. Int J Epidemiol. 2007;36:195–202
  15. Zar JH. Biostatistical analysis. 2nd ed.. Englewood Cliffs, NJ: Prentice-Hall Inc; 1984;
  16. Linzer M, Myerburg RJ, Kutner JS, et al. ASP Workforce Committee Exploring the generalist-subspecialist interface in internal medicine. Am J Med. 2006;119:528–537
  17. Moshkovska T, Mayberry JF. Duration of treatment with 5-aminosalicylic acid compounds. World J Gastroenterol. 2007;13:4310–4315
  18. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99;:1371–1385
  19. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20–22
  20. Holtmann MH, Krummenauer F, Claas C, et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci. 2006;51:1516–1524
  21. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;24:CD000478
  22. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20–22
  23. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47–53
  24. Hilsden RJ, Verhoef MJ, Best A, Pocobelli G. A national survey on the patterns of treatment of inflammatory bowel disease in Canada. BMC Gastroenterol. 2003;3:10
  25. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:207–215
  26. Vind I, Riss L, Jess T, et al. Increasing Incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn Colitis Database. Am J Gastroenterol. 2006;101:1274–1282
  27. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476Erratum in N Engl J Med 2006;354:2200
  28. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352:2499–2507
  29. Ingle SB, Loftus EV, Harmsen WS, et al. Hospitalizations and inpatient corticosteroid usage among Crohn's disease patients from Olmsted County, Minnesota, 1970-2001. Presented at Digestive Diseases Week; May 19-24, 2007; Washington DC.
  30. Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol. 2006;101:110–118
  31. Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2007;5:597–601
  32. Kappelman MD, Bousvaros A, Hyams J, et al. Intercenter variation in initial management of children with Crohn's disease. Inflamm Bowel Dis. 2007;13:890–895
  33. Altschuler A, Velayos F, Allison JE, et al. Gastroenterologists' attitudes and self-reported practices regarding inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:992–999

 Conflicts of interest The authors disclose no conflicts.

 The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

 Funding This research was funded by a contract from the Crohn's and Colitis Foundation under a cooperative agreement with the Centers for Disease Control, Atlanta, GA, and by a grant from the Kaiser Foundation Research Institute, Oakland, CA. This study was approved by the Kaiser Permanente Northern California Institutional Review Board, Oakland, CA, on December 19, 2005.

PII: S0016-5085(09)00744-6

doi: 10.1053/j.gastro.2009.04.063

Gastroenterology
Volume 137, Issue 2 , Pages 502-511 , August 2009

Article Tools

* Image Usage & Resolution